Immunocore Holdings ADR saw a positive improvement to its Relative Strength (RS) Rating on Thursday, with an increase from 67 to 77.
Can You Really Time The Stock Market?
This proprietary rating identifies technical performance by using a 1 (worst) to 99 (best) score that indicates how a stock's price performance over the last 52 weeks stacks up against all the other stocks in our database.
History reveals that the best stocks often have an 80 or better RS Rating as they launch their biggest price moves. See if Immunocore Holdings ADR can continue to show renewed price strength and hit that benchmark.
Immunocore Holdings ADR is not currently near a potential buying area. See if the stock goes on to form a chart pattern that could launch a new move.
Immunocore Holdings ADR showed 0% EPS growth in the latest quarterly report. Sales increased 36%. The company is expected to report its latest earnings and sales numbers on or around Aug. 6.
Immunocore Holdings ADR earns the No. 50 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and Inhibrx Biosciences are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
